Article

Mass. Eye and Ear joins AMD trial

Massachusetts Eye and Ear Infirmary has received institutional review board approval to be a site for Advanced Cell Technology’s phase I/II clinical trial for nonexudative (dry) age-related macular degeneration (AMD), using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.

Marlborough, MA-Massachusetts Eye and Ear Infirmary has received institutional review board approval to be a site for Advanced Cell Technology’s phase I/II clinical trial for nonexudative (dry) age-related macular degeneration (AMD), using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.

The trial is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD. The trial ultimately will enroll 12 patients, with cohorts of three patients each in an ascending dosage format.

“Dry AMD represents one of the largest unmet medical needs in ophthalmology,” said Dean Eliott, MD, a retinal surgeon, scientist, and associate director of the Retina Service at Mass. Eye and Ear. “We appreciate the opportunity to get some first-hand experience with the protocol and be involved with the international team that has been assembled around the U.S. and European trials.”

“We are delighted to announce that Mass. Eye and Ear will participate as a site for our clinical trial for dry AMD,” said Gary Rabin, Advanced Cell Technology’s chairman and chief executive officer. “Dr. Eliott and his team are deeply committed to finding new treatments for preventing blindness, and we very much look forward to tapping into his expertise and insight into the progression of macular degenerative disorders.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.